000			02005 a2200529 4500
005			20250516101540.0
264		0	_c20130329
008			201303s 0 0 eng d
022			_a1569-8041
024	7		_a10.1093/annonc/mds202 _2doi
040			_aNLM _beng _cNLM
100	1		_aMorschhauser, F
245	0	0	_aA 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. _h[electronic resource]
260			_bAnnals of oncology : official journal of the European Society for Medical Oncology _cOct 2012
300			_a2687-2695 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntibodies, Monoclonal, Murine-Derived _xtherapeutic use
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aHematopoietic Stem Cell Transplantation
650	0	4	_aHumans
650	0	4	_aLymphoma, Follicular _xdrug therapy
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm, Residual
650	0	4	_aPolymerase Chain Reaction
650	0	4	_aProspective Studies
650	0	4	_aRituximab
650	0	4	_aYoung Adult
700	1		_aRecher, C
700	1		_aMilpied, N
700	1		_aGressin, R
700	1		_aSalles, G
700	1		_aBrice, P
700	1		_aVey, N
700	1		_aHaioun, C
700	1		_aColombat, P
700	1		_aRossi, J F
700	1		_aDeconinck, E
700	1		_aLazreg, F
700	1		_aBergougnoux, L
700	1		_aDelsol, G
700	1		_aAttal, M
773	0		_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 23 _gno. 10 _gp. 2687-2695
856	4	0	_uhttps://doi.org/10.1093/annonc/mds202 _zAvailable from publisher's website
999			_c21922557 _d21922557